CS56892A3 - Process for industrially preparing standardized extremely pure concentrateof human von willebrand factor, suitable for therapeutical application - Google Patents

Process for industrially preparing standardized extremely pure concentrateof human von willebrand factor, suitable for therapeutical application

Info

Publication number
CS56892A3
CS56892A3 CS92568A CS56892A CS56892A3 CS 56892 A3 CS56892 A3 CS 56892A3 CS 92568 A CS92568 A CS 92568A CS 56892 A CS56892 A CS 56892A CS 56892 A3 CS56892 A3 CS 56892A3
Authority
CS
Czechoslovakia
Prior art keywords
concentrateof
von willebrand
willebrand factor
extremely pure
human von
Prior art date
Application number
CS92568A
Other languages
English (en)
Inventor
Miryana Burnouf-Radosevich
Thierry Burnouf
Original Assignee
Centre Regional De Transfusion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional De Transfusion filed Critical Centre Regional De Transfusion
Publication of CS56892A3 publication Critical patent/CS56892A3/cs
Publication of CZ283633B6 publication Critical patent/CZ283633B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CS92568A 1991-03-08 1992-02-26 Způsob průmyslové přípravy standardizovaného koncentrátu lidského von Willebrandova faktoru o velmi vysoké čistotě, vhodného pro terapeutické použití CZ283633B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102804A FR2673632A1 (fr) 1991-03-08 1991-03-08 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (2)

Publication Number Publication Date
CS56892A3 true CS56892A3 (en) 1992-09-16
CZ283633B6 CZ283633B6 (cs) 1998-05-13

Family

ID=9410505

Country Status (29)

Country Link
US (1) US5408039A (cs)
EP (1) EP0503991B1 (cs)
JP (1) JP3435668B2 (cs)
AT (1) AT407115B (cs)
AU (1) AU645172B2 (cs)
BE (1) BE1004178A3 (cs)
BR (1) BR9200770A (cs)
CA (1) CA2062340C (cs)
CZ (1) CZ283633B6 (cs)
DE (2) DE69227055T2 (cs)
DK (1) DK0503991T3 (cs)
EE (1) EE03057B1 (cs)
EG (1) EG20300A (cs)
ES (1) ES2121830T3 (cs)
FI (1) FI106721B (cs)
FR (1) FR2673632A1 (cs)
HU (1) HU215098B (cs)
IL (1) IL101043A (cs)
IT (1) IT1256692B (cs)
LT (1) LT3175B (cs)
NL (1) NL300394I1 (cs)
NO (1) NO301278B1 (cs)
NZ (1) NZ241701A (cs)
PL (1) PL168353B1 (cs)
RU (1) RU2088590C1 (cs)
SA (1) SA92120446B1 (cs)
SK (1) SK279533B6 (cs)
UA (1) UA27732C2 (cs)
ZA (1) ZA921430B (cs)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
RU2200028C2 (ru) * 2000-06-20 2003-03-10 Кировский НИИ гематологии и переливания крови Способ пломбировки пункционного канала после диагностической эндоскопической пункционной биопсии печени у больных гемофилией а
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
EP2467166A2 (en) 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
EP2652491B1 (en) 2010-12-15 2017-11-29 Baxalta GmbH Eluate collection using conductivity gradient
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
US9393289B2 (en) 2011-10-18 2016-07-19 Csl Behring Gmbh Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
ES2693380T3 (es) * 2013-11-08 2018-12-11 Csl Limited Nuevo método para concentrar el factor de von Willebrand o complejos de este
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
CN108473530B (zh) * 2015-10-15 2022-12-23 普莱泽玛科技有限公司 从血浆中提取蛋白质的方法
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
CN105622747A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种vWF活性保护液
CN105541997A (zh) * 2016-02-04 2016-05-04 江西博雅生物制药股份有限公司 一种高纯度和高活性血管性血友病因子的制备工艺
CN105622746A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
CN114249812B (zh) * 2020-09-22 2023-09-15 四川远大蜀阳药业有限责任公司 一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166542A (ja) * 1985-01-18 1986-07-28 Hitachi Chem Co Ltd 感光性組成物
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5006642A (en) * 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Also Published As

Publication number Publication date
EP0503991B1 (fr) 1998-09-23
AU645172B2 (en) 1994-01-06
BE1004178A3 (fr) 1992-10-06
ZA921430B (en) 1992-11-25
FI920992A0 (fi) 1992-03-06
UA27732C2 (uk) 2000-10-16
IT1256692B (it) 1995-12-12
EP0503991A1 (fr) 1992-09-16
IL101043A0 (en) 1992-11-15
SA92120446B1 (ar) 2004-05-04
FR2673632B1 (cs) 1995-05-05
FI920992L (fi) 1992-09-09
CA2062340C (fr) 2000-05-09
BR9200770A (pt) 1992-11-17
LT3175B (en) 1995-02-27
JPH0597696A (ja) 1993-04-20
ES2121830T3 (es) 1998-12-16
IL101043A (en) 1997-02-18
EE03057B1 (et) 1997-12-15
DK0503991T3 (da) 1999-06-14
AU1113192A (en) 1992-09-10
SK279533B6 (sk) 1998-12-02
ATA43692A (de) 2000-05-15
RU2088590C1 (ru) 1997-08-27
HUT63176A (en) 1993-07-28
CA2062340A1 (fr) 1992-09-09
HU9200767D0 (en) 1992-05-28
DE122009000034I2 (de) 2011-06-16
NL300394I1 (nl) 2009-09-01
NO920867L (no) 1992-09-09
ITTO920189A0 (it) 1992-03-06
NZ241701A (en) 1994-10-26
AT407115B (de) 2000-12-27
PL293738A1 (en) 1992-09-21
CZ283633B6 (cs) 1998-05-13
ITTO920189A1 (it) 1993-09-06
LTIP266A (en) 1994-07-15
DE69227055D1 (de) 1998-10-29
EG20300A (fr) 1998-10-31
US5408039A (en) 1995-04-18
FR2673632A1 (fr) 1992-09-11
DE69227055T2 (de) 1999-04-22
NO301278B1 (no) 1997-10-06
NO920867D0 (no) 1992-03-05
DE122009000034I1 (de) 2010-04-08
JP3435668B2 (ja) 2003-08-11
HU215098B (hu) 1998-09-28
PL168353B1 (pl) 1996-02-29
FI106721B (fi) 2001-03-30

Similar Documents

Publication Publication Date Title
HUT63176A (en) Process for large scale production of high purity, pharmaceutically applicable, standardized human von willebrand factor concentrate
SG94682A1 (en) Process for preparing 2,6-naphthalene-dicarboxylic acid
HU903977D0 (en) Process for producing substituted pyrimidone-sulphone derivatives and containing them insecticide and acaricide means
IL110861A (en) Process for preparing pure ethylediaminetetra (methylenphosphonic acid)
AR244757A1 (es) Metodo para preparar un pigmento de dioxido de titanio.
HU914060D0 (en) Medical preparation and process for its production
HU892994D0 (en) Process for the production of stabil medical preparations
HU911750D0 (en) Process for the production of medical preparations containing substituted betha-hydroxy-ethylamines
HU913430D0 (en) 2-substituted-methyl-aryl-carboxylates, medical preparations containing them and process for their production
EP0551596A3 (en) Process for producing naphtalenedicarboxylic acid
YU162289A (en) Process for producing titanium oxide
HUT53802A (en) Process for producing pharmaceutical preparations containing piperidino-alkanole-derivatives
GB2215720B (en) Process for preparing n-phosphono-methyl-imino-diacetic acid
EP0496264A3 (en) Process for preparing 2,6-naphthalenedicarboxylic acid
HUT50505A (en) Process for producing recombinante human interleukin-1-alpha-polypeptides
SG52396A1 (en) Process for preparing purified 2,6-naphtalenedicorboxylic acid
HU9201117D0 (en) Substituted 2',3'-didezoxy-5-trifluor-methyl-uridine, and process for the production of medical preparations containing such compounds
GB8819444D0 (en) Spread & process for preparing spread
YU4286A (en) PROCESS FOR PREPARING NEW 12-AMINOPYRIDAZINO(4',5'3,4(PYROLO)2,1-a)IZOCHYNOLINES
YU96988A (en) Process for preparing 4,4'-dinitrostilbene-2,2'-disulphonic acid
EP0534449A3 (en) Process for the preparation of 3-aminomethyl-3,5,5-trialkylcyclohexylamine
GR3023608T3 (en) Novel process for preparing 4-amino-5-hexenoic acid
EP0522577A3 (en) Process for the preparation of pure 3,3',4,4'-tetraaminobiphenyl
EP0219295A3 (en) Process for producing human growth hormone
EP0510490A3 (en) Process for preparing 2,3,4,5-tetrafluorobenzoic acid

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20100226